IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Similar documents
Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

Implementation of disease and safety predictors during disease management in UC

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

Current management options and recent advances in IBD

What s new in IBD? Dr AB Hawthorne Consultant Gastroenterologist University Hospital of Wales Cardiff

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

The York Faecal Calprotectin Care Pathway for use in primary care. James Turvill

PEDIATRIC INFLAMMATORY BOWEL DISEASE

INFLAMMATORY BOWEL DISEASE

Optimizing Management using CRP, Fecal Calprotectin and Ferritin. Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest

Efficacy and Safety of Treatment for Pediatric IBD

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Dr David Rowbotham. The Leeds Teaching Hospitals NHS Trust NHS

Medical therapies and IBD

Title: Author: Journal:

Guideline Ulcerative colitis: management

Improving outcome of Inflammatory Bowel Disease in children

Personalized Medicine in IBD

Doncaster & Bassetlaw Medicines Formulary

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

Mucosal healing: does it really matter?

This information explains the advice about Crohn's disease that is set out in NICE guideline CG152.

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Efficacy and Safety of Treatment for Pediatric IBD

SWL Drug Pathway Ulcerative Colitis Version 3 (Oct 2018) (based on NICE ulcerative colitis commissioning algorithm - with local adaptation)

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

ULCERATIVE COLITIS FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS

Inflammatory Bowel Disease

Gastroenterologist & Hepatologist Auckland City Hospital Auckland

September 12, 2015 Millie D. Long MD, MPH, FACG

Ali Keshavarzian MD Rush University Medical Center

Inflammatory bowel disease. Kawa Obeid, PhD

Faecal Calprotectin. Reliable Non-Invasive Discrimination Between Inflammatory Bowel Disease (IBD) & Irritable Bowel Syndrome (IBS)

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Treating Crohn s and Colitis in the ASC

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Irritable Bowel Syndrome vs Inflammatory Bowel Disease

-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES

A Case of Inflammatory Bowel Disease

Medical Therapy for Pediatric IBD: Efficacy and Safety

Understanding Inflammatory Bowel Diseases (IBD):

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

Achieving Success in Ulcerative Colitis: the Role of Infliximab

National Institute for Health and Care Excellence

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

How to manage your IBD patient: Tips for diagnosis and care

DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.

What is ulcerative colitis?

Diarrhoea for the Acute Physician

Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152

Protocol for the management of acute severe ulcerative colitis in children

WHAT IS ULCERATIVE COLITIS?

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Personalized Medicine in IBD: Where Are We in 2013

Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Common Questions in Crohn s Disease Therapy. Case

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

Pharmacotherapy of Inflammatory Bowel Disorder

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

IBD What s in it for you?

Disease Management Strategies for Moderate to Severe IBD in Adults

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Michael D. Kreines, M.D.

Exclusive Elemental Nutrition-Children s Perceptions Siobhain Kiernan RGN, RCN, RNP, Msc in Nursing

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Research Article The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

Update on IBD. Dr Richard POLLOK Consultant Gastroenterologist and Honorary Senior Lecturer. Queen Mary s Hospital. St George s Hospital

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

What is Crohn's disease?

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Controversies in IBD: Resolving clinical dilemmas using Cochrane reviews

THE NEW ZEALAND MEDICAL JOURNAL

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease

Management of the Hospitalized IBD Patient. Drew DuPont MD

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

Pediatric Inflammatory Bowel Diseases

Fecal Calprotectin Reliable, Novel, Noninvasive Biomarker. Bahar Allahverdi MD,TUMS,CMC Hospital Bahare Yaghmaie MD,TUMS,CMC Hospital

Pharmacotherapy of Inflammatory Bowel Disorder

Recent Advances in the Management of Refractory IBD

CROHN S & COLITIS UK SUPPORTING YOU

10/23/2014. Program Goals

Infliximab (Remicade) for paediatric ulcerative colitis - second line

Crohn s Disease. Questions & Answers

Pediatric Inflammatory Bowel Disease in Less Than 30 Minutes

young people concise guidance

Transcription:

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that IBD has on patients Diagnostics - Faecal Calprotectin Therapeutics The rise of the biologic Referral Pathways 1

Prevalence of IBD worldwide 2

Inflammatory Bowel Disease Crohn s vs UC Pathogenesis of IBD 3

14% of IBD patients have a FH Lifestyle factors that expose children to bacteria reduce IBD risk Stress, anxiety and depression are associated with IBD risk Western Diets are associated with IBD Smoking is associated with Crohn s and a reduced risk of UC IBD significantly impacts Quality of Life 40% report making adjustments to their working life based on IBD 35% report that IBD has prevented them pursuing an intimate relationship 26% report that IBD has gotten in the way of making and keeping frieds Lonnfors, et al. IBD and health related quality of life Discovering the true impact. Journal of Crohn's and Colitis. 2014; 8: 1281 1286. IBD and Quality of Life Lonnfors, et al. IBD and health related quality of life Discovering the true impact. Journal of Crohn's and Colitis. 2014; 8: 1281 1286. 4

Assessment of IBD Patients Clinical Serology Endoscopy Histological Faecal Faecal Calprotectin Calprotectin secreted in excess into the intestinal lumen during inflammation Sensitive but non-specific marker Recommended for use in Primary and Secondary Care. 1 Available from primary care PoC kits available 1. NICE Technology appraisal. Oct 2013. DG11 Calprotectin levels and Diagnosis Menees et al. Am J Gastroenterol 2015; 110:444 454 5

Calprotectin Levels and Findings at colonoscopy Colonoscopy AUC of 0.863 Sens 72.3% Spec 88.7% (57.4% vs. 7.4%, P < 0.001). Burri et al. BMC Gastroenterology 2014, 14:57 Calprotectin and cut-off ranges But this PPV and NPV can only calculated understanding the prevalence of the target condition within the population. In most settings in the UK the prevalence of IBD is less than 1% - This would raise the NPV to nearly 100%. Dhaliwal et al, Frontline Gastro 2015;6:14-19 Predicting Relapse in UC patients Clinical History and Phenotype - Onset age - Extensive Colitis - No of relapses Faecal Calprotectin (repeated sampling) At least 1 Faecal Calprotectin above 200mcg/g Close Monitoring Aggressive treatment Thiopurines Anti-TNF s 6

Calprotectin and histological remission Magro et al. JCC 2016:1-10 Calprotectin Predicts. IBD Relapse (Theede et al, Inflamm Bowel Dis 2016, May;22:5. 1042-8) Endoscopic severity in UC (Kawashima et al, BMC gastro, 2016. 16;47.) Histological response in UC (Theede et al, Inflamm Bowel Dis 2016, May;22:5. 1042-8) Pouchitis (Pronio et al, Rev Esp Enferm Dig, 2016, 108;4:190-195) Quality of Life in IBD patients (Gauss et al, 2016. Medicine. Apr:95(16):e3477) Predicting Relapse in Crohn s patients Clinical History and Phenotype - Onset age - Extensive Disease - Perianal Involvement - Steroids at diagnosis - No of surgeries Faecal Calprotectin (repeated sampling) CRP At least 1 Faecal Calprotectin above 250mcg/g CRP>10 Close Monitoring Aggressive treatment Thiopurines Anti-TNF s 7

Calprotectin and Relapse after Crohn s Surgery UK Anti-TNF withdrawal study group APT, 2016;Feb 19. Calprotectin and cancer Turvill et al 2016. British Journal of G Calprotectin can be abnormal in NSAID s (Rendek Z et al, Scand J Gastroenterol 2016. 51;1:28-32.) Previous Surgery (Boerlage TC et al, Obes Surg. 2016 May 23) PPI Use (M Cohen BJGP June 2016) Coeliac Disease (Capone et al, WJG 2014. 14;20:611-620) UGI Cancers (Vincent Z et al, Ann Clin Biochem 2015; 52:660-4) 8

Faecal Calprotectin in Primary Care Turvill et al, Primary health care R+D, 2016. Calprotectin for monitoring of Infectious Diarrhoea Stool MC+S positive Calprotectin at baseline Ongoing Symptoms (and normal CRP) Calprotectin 4-6 weeks later <100 treat as postinfectious IBS 100-250 repeat in 4 weeks >250 refer to Gastroenterology Urgent IBD referral pathway - RLUH Age under 50 Bloody Diarrhoea Faecal Calprotectin >250 Stool MC+S/CDT negative Bloods Telephone Assessment Flexible Sigmoidoscopy Within 1 week IBD 5ASA Steroids Urgent IBD Non-IBD Rpt Calpro OPD Colon If Severe as per T+W criteria CRP>30 Hb <100 Alb <30 Pyrexial Discuss with IBD Dr Fax : - 0151 7065832 Age under 50 Diarrhoea Faecal Calprotectin >250 Stool MC+S/CDT negative Bloods (UE,LFT,FBC,CRP,tTg) Telephone Assessment Urgent Colonoscopy IBD TRIALS Budesonide Urgent IBD Unclear Rpt Calpro CT Abdo or VCE if still 9

20 TH CENTURY 21 st Century Steroids Surgery 5-ASA Azathioprine Step treatment pathways Biologics (with drug and antibody monitoring) Thiopurines (with metabolite monitoring) Therapeutic endoscopy Biomarkers Minimally invasive surgery IBD Medications 5ASA Cyclosporin Anti-TNF Biosimilars Vedolizumab Surgery Steroids Thiopurine Methotrexate IBD Drugs and Prices Annual Cost Prednisolone - Steroid Beclomethasone - Steroid Mesalazine (Pentasa 2gm OD) 100-430 5ASA Methotrexate 36 Antimetabolite Azathioprine 80 Thiopurine 6 Mercaptopurine 1600 Thiopurine Infliximab 10,584 Anti-TNF Biosimilar Infliximab 6800 Anti-TNF Golimumab 9155 Anti-TNF Adalimumab 9528 Anti-TNF Vedolizumab 16,913 Anti-Integrin Ustekinumab 10,735 Anti-IL23 10

Treatments POST diagnosis Ulcerative Colitis Salofalk Granules 3gm (Left sided) or Pentasa Granules 4gm (Pancolitis) 5-ASA enema (foam or liquid) for Left sided disease 5-ASA suppository for proctitis Rectal Steroids Clipper 5mg Prednisolone for severe Crohn s 5-asa for colonic disease Budesonide for Ileal disease?antibiotics?enteral Nutrition Flaring Patient Nurse-led IBD help-line Phone number Royal Liverpool 0161 7062659 Aintree 0151 5294801 Whiston 0151 2904417 Prescriptions Problems related to Disease modifying drugs Conclusions Expanding availability of high cost drugs poses resource challenges Drug monitoring and Biosimilars may mitigate this Faecal Calprotectin allows us to approach diagnosis in new ways Wide availability of IBD helplines New pathways for Urgent referrals 11

12